H. Hill

发表

Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children

K. Edwards, E. Walter, J. Englund, 2014, The Pediatric infectious disease journal.

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.

D. Bernstein, M. Mulligan, D. Ince, 2014, JAMA.

Impact of Body Mass Index on Immunogenicity of Pandemic H 1 N 1 Vaccine in Children and Adults

K. Edwards, H. Hill, S. Callahan, 2014 .

Determination of the 50% human infectious dose for Norwalk virus.

D. Graham, M. Estes, S. Crawford, 2014, The Journal of infectious diseases.

Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.

W. Keitel, Shital M. Patel, R. Atmar, 2012, The Journal of infectious diseases.

A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.

A. Jansen, R. Curtiss, K. Lottenbach, 2013, Vaccine.

Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

D. Fisher, M. Seaman, K. Verrill, 2013, The Journal of infectious diseases.

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

D. Bernstein, K. Edwards, R. Belshe, 2008, The Journal of infectious diseases.

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

W. Keitel, Shital M. Patel, E. Walter, 2008, The Journal of infectious diseases.

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

J. Treanor, D. Noah, T. Rowe, 2008, The Journal of infectious diseases.

Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.

K. Schmader, M. Mulligan, W. Keitel, 2014, The Journal of infectious diseases.

Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.

Andrea A. Berry, D. Bernstein, K. Edwards, 2015, Journal of the Pediatric Infectious Diseases Society.

Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine.

R. Couch, T. Cate, W. Keitel, 2011, Vaccine.

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.

M. Mulligan, R. Belshe, A. Wald, 2011, The Journal of infectious diseases.

Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.

K. Schmader, D. Bernstein, M. Mulligan, 2021, Vaccine.

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.

T. Cate, R. Frenck, K. Edwards, 2011, Vaccine.

Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine

Travis L. Jensen, Johannes B. Goll, J. Wrammert, 2020, Vaccines.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old

M. Mulligan, W. Keitel, Shital M. Patel, 2015, The Journal of infectious diseases.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated In fl uenza A ( H 3 N 2 ) Variant Vaccine in Healthy Persons ≥ 18 Years Old

M. Mulligan, W. Keitel, Shital M. Patel, 2015 .

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Andrea A. Berry, W. Keitel, Shital M. Patel, 2015, JAMA.

Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Johannes B. Goll, W. Keitel, Shital M. Patel, 2016, Vaccine.

M. Mulligan, W. Keitel, Wilbur H. Chen, 2021, Clinical & translational immunology.

A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.

H. Mulla, S. Frey, G. Gorse, 2022, Vaccine.

Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine Licensure

D. Noah, E. White, M. Wolff, 2009, Clinical and Vaccine Immunology.

First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E

E. Walter, M. Cohen-Wolkowiez, Y. Espinoza, 2022, Antimicrobial agents and chemotherapy.

Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B

E. Walter, M. Cohen-Wolkowiez, V. Juel, 2021, Antimicrobial agents and chemotherapy.

Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.

Johannes B. Goll, M. Mulligan, W. Keitel, 2017, Vaccine.

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.

W. Keitel, R. Belshe, J. Treanor, 2009, Vaccine.

Vaccine With MF59 Adjuvant A Randomized Clinical Trial

C. Woods, M. Mulligan, K. Edwards, 2017 .

Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.

C. Woods, M. Mulligan, K. Edwards, 2014, JAMA.

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

Michael R. Wierzbicki, Tom M. Conrad, Cameron R. Wolfe, 2021, The Lancet Respiratory Medicine.

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Johannes B. Goll, S. El-Kamary, M. Mulligan, 2017, Vaccine.

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

S. El-Kamary, F. Newman, R. Belshe, 2013, Vaccine.

Safety and Immunogenicity of Modi ﬁ ed Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial

D. Fisher, M. Seaman, K. Verrill, 2013 .

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

W. Keitel, Shital M. Patel, K. Edwards, 2015, Clinical and Vaccine Immunology.

Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.

Johannes B. Goll, Shital M. Patel, K. Edwards, 2016, The Journal of infectious diseases.

MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.

H. Mulla, S. Frey, G. Gorse, 2022, Vaccine.

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

W. Keitel, Shital M. Patel, K. Edwards, 2009, Vaccine.

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Catharine I Paules, R. Hyzy, M. Proschan, 2022, The Lancet Respiratory Medicine.

Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

R. Ray, M. Houghton, R. Belshe, 2010, Vaccine.

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses

Michael John Smith, E. Walsh, A. Falsey, 2022, medRxiv.

Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.

M. Mulligan, A. Wald, C. Dekker, 2012, The Journal of infectious diseases.

Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Johannes B. Goll, R. Belshe, P. Winokur, 2014, Vaccine.

Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.

S. Frey, M. Ewell, H. Hill, 2015, Vaccine.

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects

Johannes B. Goll, S. El-Kamary, M. Mulligan, 2015, Vaccine.

Retrospective Analysis of Pneumonic Tularemia in Operation Whitecoat Human Subjects: Disease Progression and Tetracycline Efficacy

T. Guina, H. Hill, Mark S Williams, 2019, Front. Med..

Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated and antibody dependent cellular cytotoxicity responses.

Travis L. Jensen, Johannes B. Goll, D. Davies, 2021, The Journal of infectious diseases.

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Lihan K. Yan, F. Ennis, B. Chaitman, 2007, Vaccine.

Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial

Travis L Jensen, Heather Hill, Johannes B Goll, 2017, PloS one.

Safety and Immunogenicity of Modi fi ed Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients : A Randomized , Controlled Trial

D. Fisher, M. Seaman, K. Verrill, 2013 .

PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4+ T cell transcriptomal molecular signatures

V. Brusic, P. Andersen, G. Matuschak, 2017, Mucosal Immunology.

Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.

Johannes B. Goll, D. Bernstein, Shital M. Patel, 2014, Vaccine.

Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

D. Bernstein, R. Belshe, D. Noah, 2012, The Journal of infectious diseases.

Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine

M. Mulligan, W. Keitel, N. Rouphael, 2020, Vaccines.

Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses

William F. Hooper, Travis L. Jensen, Johannes B. Goll, 2019, Vaccines.

Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial

D. Bernstein, M. Mulligan, N. Rouphael, 2014, Open forum infectious diseases.

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant

W. Keitel, Shital M. Patel, K. Edwards, 2014, Open forum infectious diseases.

Proteomics show antigen presentation processes in human immune cells after AS03‐H5N1 vaccination

Travis L. Jensen, Johannes B. Goll, A. Link, 2017, Proteomics.

High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.

P. Winokur, J. Stapleton, A. Bellamy, 2020, Vaccine.

A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.

D. Ferris, D. Kasper, L. Meyn, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial

A. Falsey, D. Montefiori, S. Little, 2023, Research square.

Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.

R. Higgins, Harry Seifert, G. Siberry, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis.

W. Keitel, R. Atmar, A. Bellamy, 2019, Vaccine.

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.

S. El-Kamary, W. Keitel, Shital M. Patel, 2015, The Journal of infectious diseases.

Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults

M. Jackson, L. Jackson, A. Bellamy, 2015, Epidemiology and Infection.

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

D. Bernstein, M. Mulligan, W. Keitel, 2015, Vaccine.

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial